Utah Medical Products' (UTMD) Sell (D+) Rating Reiterated at Weiss Ratings

Key Points

• Utah Medical Products' stock has been assigned a "sell (D+)" rating by Weiss Ratings, reflecting analysts' cautious outlook on the company's performance.
• The company reported a net margin of 32.34% and earnings per share of $0.94 alongside a quarterly revenue of $9.95 million.
• Institutional investors hold 69.60% of Utah Medical Products' stock, with significant increases in holdings from firms like Allspring Global Investments and GAMMA Investing.

Utah Medical Products (NASDAQ:UTMD - Get Free Report)'s stock had its "sell (d+)" rating reiterated by research analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

Utah Medical Products Stock Up 0.3%

Shares of NASDAQ UTMD traded up $0.21 during mid-day trading on Wednesday, hitting $63.43. 7,237 shares of the company were exchanged, compared to its average volume of 7,989. The stock has a 50 day simple moving average of $60.64 and a 200-day simple moving average of $57.01. The firm has a market cap of $203.61 million, a price-to-earnings ratio of 16.96 and a beta of 0.32. Utah Medical Products has a 1-year low of $51.26 and a 1-year high of $68.99.

Utah Medical Products (NASDAQ:UTMD - Get Free Report) last posted its quarterly earnings results on Thursday, July 24th. The medical instruments supplier reported $0.94 earnings per share for the quarter. The business had revenue of $9.95 million for the quarter. Utah Medical Products had a net margin of 32.34% and a return on equity of 10.55%.

Institutional Trading of Utah Medical Products

A number of institutional investors have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC increased its position in shares of Utah Medical Products by 12.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 13,119 shares of the medical instruments supplier's stock valued at $735,000 after buying an additional 1,421 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Utah Medical Products by 134,400.0% in the 1st quarter. GAMMA Investing LLC now owns 4,035 shares of the medical instruments supplier's stock worth $226,000 after buying an additional 4,032 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Utah Medical Products by 19.2% in the 4th quarter. Bank of America Corp DE now owns 4,928 shares of the medical instruments supplier's stock worth $303,000 after buying an additional 795 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Utah Medical Products by 2.7% in the 1st quarter. Bank of New York Mellon Corp now owns 48,612 shares of the medical instruments supplier's stock worth $2,724,000 after buying an additional 1,277 shares in the last quarter. Finally, Nuveen LLC purchased a new stake in shares of Utah Medical Products in the 1st quarter worth about $449,000. 69.60% of the stock is currently owned by hedge funds and other institutional investors.

About Utah Medical Products

Utah Medical Products, Inc develops, manufactures, and distributes medical devices for the healthcare industry worldwide. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.